📅 Webinar reminder!
Join us this Friday for @kjarmache.bsky.social webinar.
More details below, or you can register here for free: us06web.zoom.us/webinar/regi...
@activemotifusa.bsky.social
Hands up if you love chromatin & structural biology 🙋♂️
On Friday April 24th we will be joined by @kjarmache.bsky.social from NYU for his webinar 'Chromatin-Modifying Complexes in Gene Activation and Silencing'.
Register here: us06web.zoom.us/webinar/regi...
@activemotifusa.bsky.social
⏰ Calling all chromatin aficionados!
We we will be joined by @adelmanlab.bsky.social from @harvardmed.bsky.social for our March 27th webinar 📅
Karen will be sharing her groups work on 'Transcription & RNA Quality Control in Health & Disease' 😷🧬
Register here: us06web.zoom.us/webinar/regi...
Only 24 hours to go to our next webinar with @brianstrahl.bsky.social !
Make sure to register for free through link below 👇
We are delighted to launch the (free!) registration for our 5th AICC symposium, hosted this year in @ucddublin.bsky.social on May 27th.
If you are interested in chromatin, gene regulation or the nucleus please join us!
allirelandchromatinconsortium.ie/annual-meeti...
Just one week to go until Edith Heard will be joining us for the All-Ireland Chromatin Consortium webinar on 'The Epigenetic Dynamics of X Inactivation in Development and Disease' 🧬
Registration link: us06web.zoom.us/webinar/regi...
@adrianbracken.bsky.social we are looking forward to your presentation at our #FusionEpigenetics meeting in Portugal this October!
Please share this with your followers to let them know you will speaking, and to register & submit today to join us
🔗 bit.ly/4rC6B45
Synovial sarcoma is driven almost exclusively by a single oncofusion – SS18-SSX
For years, the assumptions on disease mechanisms were simple:
➡️ SS18-SSX works by hijacking SWI/SNF chromatin remodeling activity
Our new study shows that assumption was wrong 🧵👇
www.biorxiv.org/content/10.6...
After a short break in our webinars we are delighted to be back up & running this month!
First up, on Jan 30th we will be joined by @lucas.farnunglab.com from @harvardmed.bsky.social 🔬
Shortly after, on Feb 13th we will be hosting @heardlab.bsky.social from @crick.ac.uk 🧬
Registration details 👇
Two alternative isoforms of PRC2 accessory subunit AEBP2 modulate developmental Polycomb functions in opposite ways - with broadly-expressed AEBP2L acting as an intrinsic inhibitor in somatic cells
@adrianbracken.bsky.social @davidovichlab.bsky.social and colleagues
www.embopress.org/doi/full/10....
We are delighted that @genesdev.bsky.social have selected our (w/ @adrianbracken.bsky.social) Weaver syndrome paper artwork as the November cover! This piece was made by my incredibly talented niece, Gina 'Dna Vinci' Ronan.
@ucddublin.bsky.social @tcddublin.bsky.social @ucd-sbbs.bsky.social
Thanks KJ. You’re exactly right. Since AEBP2-L is the broadly expressed isoform, it needs to get more attention. Chen’s lab did a great job of figuring out how its disordered N-terminal region works. What’s also cool is that it binds to PRC2 without JARID2 in many somatic cell types
16/ 📖 Again, please check out the full paper here: surl.li/cgwqcq
Huge thanks again to all collaborators and co-authors who made this project possible! 🙏
15/ This work highlights how evolution created a regulatory switch within a single protein isoform to restrain PRC2 activity in somatic tissues — a major step toward understanding PRC2 regulation during development, but also has relevance in terms of PRC2 dysregulation in cancer surl.li/jkrdbt
14/ 💡 Key insight: We found that AEBP2-L ⏸️ acts as a brake on PRC2 in somatic cells, whereas AEBP2-S ⚡ boosts PRC2, but is only present in very early development.
Since most studies focus on AEBP2-S, we feel it's time the broadly expressed AEBP2-L 👀 gets the attention it deserves!
13/ ⚙️ Mechanistically, AEBP2-L contains a mammalian-specific, disordered N-terminal region with acidic tracts that we find inhibit PRC2 binding to chromatin. Mutations that neutralize this region relieve inhibition and boost H3K27 methyltransferase activity:
12/ Interestingly, across mouse & human tissues, AEBP2-L is the predominant isoform from early embryogenesis, and broadly expressed.
Strikingly, the AEBP2-S isoform, which most labs study, is barely expressed beyond very early development!! 🤯
11/ We next wished to explore PRC2 integrity in the absence of AEBP2 isoforms with @michielvermeulen.bsky.social. We found that while loss of either isoform reduced JARID2 incorporation, JARID2 can associate with PRC2.2 with either isoform or even without both
10/ Indeed, loss of AEBP2-S KO impaired repression of 398 genes normally silenced by PRC2 during differentiation, whereas loss of AEBP2-L did not cause any defect
9/ If AEBP2-L acts like a Trithorax group protein, could AEBP2-S act like a Polycomb group protein? 🤔 We examined the roles of both isoforms during naive-to-primed pluripotency differentiation, which we previously used to study JARID2 during differentiation pubmed.ncbi.nlm.nih.gov/37030288/
8/ Notably, complete loss of AEBP2 (both isoforms) was shown by Brockdorff & Cooper (2016) to produce a Trithorax phenotype in mice, accompanied by increased PRC2 and H3K27me3 at target genes ⬆️
pubmed.ncbi.nlm.nih.gov/27317809/
7/ AEBP2-L acts like a Trithorax group protein! 😲 We found that loss of AEBP2-L, but not AEBP2-S, increases ⬆️ PRC2 binding and H3K27me3 deposition on PcG target genes, mirroring the effect of losing both isoforms
6/ Next, to avoid any potential overexpression issues, we used CRISPR 🧬✂️ to KO either the short, the long or both isoforms in mouse ESCs:
5/ We then confirmed in cells that ectopically expressed AEBP2-L does not binds PcG target genes as well as AEBP2-S. Curiously, ectopic overexpression of AEBP2-L, but not AEBP2-S, reduced overall SUZ12 (PRC2) binding ⬇️⬆️
4/ 🔍We focused on AEBP2, a PRC2 accessory subunit with two isoforms: AEBP2-S (short) and AEBP2-L (long).
Strikingly, we found AEBP2-L inhibits DNA binding by PRC2, whereas AEBP2-S promotes it:
3/ PRC2 is a chromatin repressor complex essential for development and deregulated in disease. While several accessory proteins enhance PRC2, no endogenous inhibitor in somatic cells had been identified — until now! ⚡️
2/ 🧵🌍 Firstly, a huge thank you to first authors Marlena Mucha, Zhihao Lai, Nicholas McKenzie, Francesca Matra. This was a joint effort with @davidovichlab.bsky.social with wonderful collaborations with labs at Radboud, NKI, USC & Garvan Institute 🙏🧵
1/ 🚀 AEBP2 isn’t what we thought.
You were told that AEBP2 promotes PRC2 activity on chromatin.
We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity.
👉 surl.li/cgwqcq
A thread 🧵
Absolutely delighted to share our preprint, using functional genomics to uncover a novel dependency in lymphoma that can overcome resistance to targeted therapy. Grateful to co-first author @jamesnolan.bsky.social and co-senior authors @conwayer1.bsky.social and @adrianbracken.bsky.social see👇
